✦ LIBER ✦

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

✍ Scribed by Mathieu, C.; Rodbard, H. W.; Cariou, B.; Handelsman, Y.; Philis-Tsimikas, A.; Ocampo Francisco, A. M.; Rana, A.; Zinman, B.

Book ID: 121855363
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 884 KB
Volume: 16
Category: Article
ISSN: 1462-8902
DOI: 10.1111/dom.12262

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of Liraglutide vs. P

Efficacy and Safety of Liraglutide vs. Placebo When Added to Basal Insulin Analogues in Subjects with Type 2 Diabetes (LIRA-ADD2BASAL): A Randomized, Placebo-Controlled Trial

✍ Conway, J Robin; Ahmann, Andrew; Rodbard, Helena; Rosenstock, Julio; Lahtela, Jo 📂 Article 📅 2014 🏛 Canadian Diabetes Association 🌐 English ⚖ 52 KB

The Efficacy and Safety of Insulin Deglu

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

✍ Meneghini, L.; Atkin, S. L.; Gough, S. C. L.; Raz, I.; Blonde, L.; Shestakova, M 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 842 KB

A Comparison of Twice-Daily Biphasic Ins

A Comparison of Twice-Daily Biphasic Insulin Aspart 70/30 and Once-Daily Insulin Glargine in Persons with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Therapy: A Randomized, Open-Label Study

✍ Ligthelm, Robert; Gylvin, Titus; DeLuzio, Tony; Raskin, Philip 📂 Article 📅 2011 🏛 American Association of Clinical Endocrinologists 🌐 English ⚖ 781 KB

Low-Volume Insulin Degludec 200 Units/mL

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

✍ Gough, S. C. L.; Bhargava, A.; Jain, R.; Mersebach, H.; Rasmussen, S.; Bergensta 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 443 KB

Response to Comment on: Bergenstal et al

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140-2147

✍ Bergenstal, R. M.; Rosenstock, J.; Arakaki, R. F.; Prince, M. J.; Qu, Y.; Sinha, 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 48 KB

PDB20 COMPARISON OF THE COST TO REACH A1

PDB20 COMPARISON OF THE COST TO REACH A1C TARGETS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE

✍ D Cobden; E Allen; M Botteman 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB